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Abstract
Background: Information regarding the prevalence of PKU in the Middle East
in comparison to other world regions is scarce, which might be explained by
difficulties in the implementation of national newborn screening programs.
Objective: This study seeks for the first time to genotype and biochemically
characterize patients diagnosed with hyperphenylalaninemia (HPA) at the
Pediatric Metabolic Genetics Clinic at the King Hussein Medical Center,
Amman, Jordan.
Methods: A total of 33 patients with HPA and 55 family members were inves-
tigated for pterins (neopterin and biopterin) and dihydropteridine reductase
(DHPR) activity in dried blood spots. Patients with HPA were genotyped for
phenylketonuria (PKU) and the genes involved in tetrahydrobiopterin (BH4)
metabolism.
Results: In total 20 patients were diagnosed with PKU due to phenylalanine
hydroxylase (PAH) deficiency, 2 with GTP cyclohydrolase I (GTPCH) defi-
ciency, 6 with DHPR deficiency, and 3 with the 6-pyruvoyl-tetrahydropterin
synthase (PTPS) deficiency. Diagnosis was not possible in 2 patients. This study
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documents a high percentage of BH4 deficiencies within HPA patients. With
one exception, all patients were homozygous for particular gene variants.
Conclusions: This approach enables differentiation between PKU and BH4
deficiencies and, thus, allows for critical selection of a specific treatment
strategies.
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1 | INTRODUCTION
Phenylketonuria (PKU; OMIM# 261600) is an autosomal
recessive metabolic disease caused by deficiency of hepatic
phenylalanine-4-hydroxylase (PAH; EC 1.14.16.1).1 PAH is
a non-heme iron enzyme that catalyses the rate-limiting
step in phenylalanine (Phe) catabolism using molecular
oxygen, iron and tetrahydrobiopterin (BH4) as cofactors.
2
If untreated, biallelic loss of function variants in the PAH
gene therefore lead to hyperphenylalaninemia (HPA) and
accumulation of Phe in the brain, causing severe intellec-
tual disability, behavioural disturbances and psychiatric
disorders in untreated patients.3 While introduction of a
Phe-restricted diet in the first 2 to 3 weeks has been shown
to nearly abolish these symptoms, some patients treated
from an early age show lower IQ scores than their mat-
ched controls, while cognitive outcomes are inversely cor-
related with blood Phe levels.4 The clear relationship
between clinical and metabolic phenotypes is the basis of
phenotype classification, which is based on blood Phe
levels before starting the treatment.5,6 Most classifications
today distinguish between mild hyperphenylalaninemia
(MHP; 120-600 μmol/L), mild PKU (mPKU; 600-
1200 μmol/L) and classic PKU (cPKU; >1200 μmol/L),
while some recognize an additional group of moderate
PKU (blood Phe 900-1200 μmol/L). The wide range of
metabolic (and clinical) phenotypes has been shown to be
mainly determined by the PAH genotype although other
factors might play a role as well.7 The large PKU database
BIOPKU (http://www.biopku.org) enables the genotypic
phenotype prediction in almost 99% of patients by the
using allelic phenotype values (APVs).8
PKU is the most common inborn error of amino acid
metabolism, affecting approximately 1 in 10 000 new-
borns in Europe.1 The prevalence of PKU ranges from
rather rare (e.g., in Japan 1:120000 and Thailand
1:122000), to very common (e.g., in the Karachay-
Cherkess Republic of Russia 1:8509 and Sicily, Italy
1:2700).10 Prevalence reports in the Arab countries are
scarce,11 and there is no solid data on the prevalence of
PKU in Jordan.12,13
In this study, we characterized patients with HPA
and their family members from the Pediatric Metabolic
Genetics Clinic at the King Hussein Medical Center,
Amman, Jordan biochemically and genetically, differenti-
ating between PKU and BH4 deficiencies.
2 | MATERIALS AND METHODS
2.1 | Patients
A total of 33 patients (13 females and 20 males; age 1 week
to 1 year and 8 months) from 25 families of Jordanian
background (East Jordan and west bank that is Palestine)
were diagnosed with HPA (blood Phe levels 205-
2107 μmol/L) at the Pediatric Metabolic Genetics Clinic at
King Hussein Medical Center, Amman, Jordan (Table 1).
Eleven clinically normal patients were diagnosed through
the newborn screening for PKU before the age of 1 week,
while all other patients were diagnosed late. They pres-
ented with developmental delay, hypotonia, spasticity,
hyperreflexia microcephaly, seizures, ADHS or abnormal
brain MRI at the time of investigations (Table 1). Consan-
guinity (first or second cousins) was reported in 19 (57%)
patients.
2.2 | Pterins and DHPR testing
With one exception (#18), all patients (n = 32) and their
parents (n = 55) were investigated for pterins (neopterin
and biopterin) and dihydropteridine reductase (DHPR)
activity in dried blood spots (DBSs). All patients with
SYNOPSIS
The paper describes for the first time genotypes
and phenotypes of PKU patients and a relative
high incidence of BH4 deficiencies in Jordan.
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abnormal Spasticity Hyperreflexia Died
1 M Second cousin 10 m 1670 3 y 4 mo + + + + +
2 F First cousin 1 wk 354 1 y 8 mo
3 F First cousin 1 y 6 mo 755 6 y 5 mo + + + + +
4 F Second cousin 2 wk 777 1 y 5 mo + + +
5 F − 1 wk 1300 2 y
6 F Second cousin 2 mo 785 3 y 5 mo +
7 M First cousin 1 y 6 mo − 5 y 11 mo + + + +
8 F − 2 mo 926 1 y 4 mo
9 M First cousin 1 wk 1240 2 y 2 mo
10 M First cousin 1 wk 1150 2 y
11 M − 1 wk 908 8 m
12 F First cousin 1 wk 1301 1 y 5 mo
13 F First cousin 1 y 6 mo 1152 20 y 9 mo + + + + +
14 M Not related 1 mo 1100 3 y 6 mo + + + + + +
15 F Not related 1 mo 400 5 y 11 mo
16 M First cousin 1 y 6 mo − 21 y 9 mo + + + +
17 M − 1 wk − 13 y 2 mo
18 M − 1 wk − 13 y 2 mo
19 M − 1 wk − 13 y 2 mo
20 M Second cousin 1 y 6 mo − 11 y 2 mo + + +
21 M First cousin − − 8 y 5 mo + + + + +
22 F First cousin 1 y 6 mo − 7 y 9 mo + +
23 M − 1 y 8 mo 288 7 y 1 mo + + +++ + + +
24 M 8 mo 205 2 y 7 mo + ++
25 F Not related 9 mo − 6 y 11 mo + + +++ + + +
26 M First cousin 7 mo − 4 y 4 mo + + ++ + + + +
27 M − − − 8 y 3 mo + + +++ + + + +
















HPA were genotyped for variations in PAH, GCH1 (GTP
cyclohydrolase 1), PTS (6-pyruvoly-tetrahydropterin
synthase) and QDPR (DHPR) genes to exclude or confirm
a possible BH4 deficiency. Pterins were measured in DBSs
using the method described by Opladen et al,14 and
DHPR activity was measured according to Arai et al.15
2.3 | DNA sequencing
DNA testing was carried out by Sanger sequencing of the
CDS regions and the exon-intron boundaries of the four
genes, following biochemical findings. For two patients,
the GTPCH feed-back regulatory protein (GFRP) and
DNAJC12 genes were also investigated. The primers and
PCR conditions used were original and are available
upon request. All sequencing reactions were performed
using a BigDyeTerminator Cycle Sequencing v1.1 kit
(ThermoFisher) and analyzed on an ABI PRISM 3130 XL
(ThermoFisher). To investigate PAH exon deletion/dupli-
cation a MLPA kit was used (MRC-Holland) according to
the manufacturer's recommendations.
APV is a value defining the association of a variant with
the corresponding metabolic phenotype, thus defining its
severity. APV was calculated for variants occurring in a
functionally hemizygous constellation (ie, in a combination
with an inactive zero-allele).8 APVs range between 0 and
10, with following classification cPKU (APV = 0-2.7),
mPKU (APV = 2.8-6.6), and MHP (APV = 6.7-10).
Whole exome sequencing was performed in two
patients for which no mutations were found in the PAH,
GCH1, PTS, QDPR, GFRP or DNAJC12 genes. Genomic
DNA of probands and their family members was extracted
from peripheral blood leukocytes using a Lab-Aid Nucleic
Acid Isolation kit (Zeesan, China), according to the manu-
facturer's instructions. Exome sequencing was performed
on genomic DNA. Capture was conducted with the xGen
Exome research panel v1.0 (Integrated DNA Technolo-
gies), and the captured DNA fragments were sequenced
by a HiSeq 4000 (Illumina). A Burrows-Wheeler Aligner
(BWA, version 0.7.10) was used to map reads to the
human reference genome (GRCh37/hg19). Base calling,
QC analysis and coverage analysis were performed with
Picard tools 1.124 and GATK software. Variants were
annotated using SnpEff version 4.2. Subsequently, the fol-
lowing variants were filtered out: (a) variants with >1%
frequency in the population variant databases, including
the 1000 Genomes Project, Exome Variant Server (EVS)
and Exome Aggregation Consortium (ExAC), or >5% fre-
quency in our in-house database (based on 150 exome
datasets), (b) intergenic and 30/50 untranslated region
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(DBS) Gene Protein variant Genotype GPVa PolyPhen2/SIFTb Phenotypenmol/g Hb
1 3 y 4 mo 0.39 0.22 36 1.7 PAH p.[Arg176*]; [Arg176*] c.[526C>T]; [526C>T] 0 - cPKU
2 1 y 8 mo 0.40 0.22 35 1.0 PAH p.[Leu197Phe]; [Leu197Phe] c.[591G>C]; [591G>C] 3.8c 1.000/0.01 mPKU
3 6 y 5 mo 0.72 0.45 38 2.0 PAH p.[Phe55Leufs*6]; [Phe55Leufs*6] c.[165del]; [165del] 0 - cPKU
4 1 y 5 mo 1.34 0.38 22 2.1 PAH p.[Arg261Gln]; [Arg261Gln] c.[782G>A]; [782G>A] 1.6 1.00/00.01 cPKU
5 2 y 0.88 0.34 28 1.2 PAH p.(?) c.[1066-11G>A];
[1066-11G>A]
0 - cPKU
6 3 y 5 mo 0.59 0.70 54 0.9 PAH p.[Arg176*]; [Arg176*] c.[526C>T]; [526C>T] 0 - cPKU
7 5 y 11 mo 0.74 0.48 39 1.3 PAH p.[Phe55Leufs*6]; [Phe55Leufs*6] c.[165del]; [165del] 0 - cPKU
8 1 y 4 mo 0.74 0.21 22 1.7 PAH p.[Phe55Leufs*6]; [Phe55Leufs*6] c.[165del]; [165del] 0 - cPKU
9 2 y 2 mo 0.27 0.09 25 2.8 PAH p.[Arg176*]; [Arg176*] c.[526C>T]; [526C>T] 0 - cPKU
10 2 y 0.32 0.11 26 1.2 PAH p.[Thr323del]; [Thr323del] c.[967_969del]; [967_969del] 0 - cPKU
11 8 mo 1.36 0.25 16 2.7 PAH p.[Thr323del]; [Thr323del] c.[967_969del]; [967_969del] 0 - cPKU
12 1 y 5 mo 0.64 0.44 41 1.7 PAH p.[Lys363Asnfs*37];
[Lys363Asnfs*37]
c.[1089del]; [1089del] 0 - cPKU
13 20 y 9 mo 0.59 0.35 37 2.7 PAH p.[Glu57del]; [Glu57del] c.[169_171del]; [169_171del] 0 - cPKU
14 3 y 6 mo 0.43 0.24 36 3 PAH p.[Arg176*]; [Arg176*] c.[526C>T]; [526C>T] 0 - cPKU
15 5 y 11 mo 0.67 0.24 26 1.6 PAH p.[Arg261Gln]; [Leu197Phe] c.[782G>A]; [591G>C] 3.8c 1.000/0.01 mPKU
16 21 y 9 mo 0.19 0.24 56 1.7 PAH p.[Tyr198Serfs*136];
[Tyr198Serfs*136]
c.[592_613del]; [592_613del] 0 - cPKU
17 13 y 2 mo 0.52 0.35 40 1.9 PAH p.[Tyr198Serfs*136];
[Tyr198Serfs*136]
c.[592_613del]; [592_613del] 0 - cPKU
18 13 y 2 mo - - - - PAH p.[Tyr198Serfs*136];
[Tyr198Serfs*136]
c.[592_613del]; [592_613del] 0 - cPKU
19 13 y 2 mo 0.22 0.11 33 2 PAH p.[Tyr198Serfs*136];
[Tyr198Serfs*136]
c.[592_613del]; [592_613del] 0 - cPKU
20 11 y 2 mo 0.2 0.08 29 3 PAH p.(?) c.[1199+1G>C]; [1199
+1G>C]
0 - cPKU
21 8 y 5 mo 0.14 0.01 7 2.4 GCH1 p.[His126Leu]; [His126Leu]d c.[377A>T]; [377A>T] 0.131/0.01 GTPCH
22 7 y 9 mo 0.03 0.03 40 2.8 GCH1 p.[His126Leu]; [His126Leu]d c.[377A>T]; [377A>T] 0.131/0.01 GTPCH
23 7 y 1 mo 0.48 0.18 27 <0,1 QDPR p.[Gly170Ser]; [Gly170Ser] c.[508G>A]; [508G>A] 0.999/0.00 DHPR




























(DBS) Gene Protein variant Genotype GPVa PolyPhen2/SIFTb Phenotypenmol/g Hb
25 6 y 11 mo 0.68 0.26 28 <0,1 QDPR p.(?) c.[436+1G>C]; [436
+1G>C]
- DHPR
26 4 y 4 mo 1 0.99 50 <0,1 QDPR p.(?) c.[545+1G>A]; [545
+1G>A]
- DHPR
27 8 y 3 mo 0.59 1.36 70 <0,1 QDPR p.(?) c.[545+1G>A]; [545
+1G>A]
- DHPR
28 10 y 5 mo 0.57 1.32 70 <0,1 QDPR p.(?) c.[545+1G>A]; [545
+1G>A]
- DHPR
29 1 y 3 mo 4.44 0.01 0 3.4 PTS p.[Thr67Met]; [Thr67Met] c.[200C>T]; [200C>T] 1.000/0.01 PTPS
30 1 y 5 mo 9.4 0.01 0 2.2 PTS p.[Asp94Gly]; [Asp94Gly]d c.[281A>G]; [281A>G] 0.875/0.05 PTPS
31 1 y 1 mo 1.63 0.02 1 2.4 PTS p.[Glu82Gly]; [Glu82Gly] c.[245A>G]; [245A>G] 0.024/0.05 PTPS
32 1 y 6 mo 1.06 0.39 27 2.7 - HPA
33 1 y 5 mo 1.26 0.31 20 2.3 - HPA
Controls 0.2-2.9 0.1-1.2 >1.4
aGPV (=APVmax): genotypic phenotype value (0-2.7 cPKU, 2.8-6.6 mPKU, 6.7-10 MHP).
bPolyPhen2 (0-0.15 = benign, 0.15-1.0 = possibly damaging, 0.85-1.0 = damaging), SIFT (0-0.05 = deleterious, 0.05-1.0 = tolerated/benign).
cBased on phenotypes of only four patients.
dVariants previously not reported. Neo, neopterin; Bio, biopterin; HPA, hyperphenylalaninemia; DHPR, dihydropteridine reductase; PAH phenylalanine hydroxylase gene (NM_000277.3);
GCH1, GTP cyclohydrolase I gene (NM_000161.3); GTPCH, GTP cyclohydrolase I; QDPR, dihydropteridine reductase gene (NM_000320.3); DHPR, dihydropteridine reductase; PTS,















SIFT (http://sift.jcvi.org), and PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2/) were used to assess the patho-
genic potential of the variants. Combined with clinical
manifestation and modes of inheritance, candidate vari-
ants were validated by Sanger sequencing and classified
according to standards and guidelines of the American
College of Medical Genetics and Genomics (ACMG). Par-
ents were not studied.
This study was approved by the local ethics commis-
sion. Written informed consent was obtained from each
adult patient or from the parent or guardian of each
child, adolescent and intellectually disabled patient
enrolled in this study.
3 | RESULTS
Out of all 33 investigated patients from Jordan,
20 patients were classified as having PKU caused by PAH
deficiency (18 cPKU and 2 mPKU), and 11 were diag-
nosed with BH4 deficiencies (6 with DHPR deficiency,
3 with PTPS deficiency and 2 with GTPCH deficiency).
For two patients, no variations were found in PAH,
GCH1, PTS, QDPR, GFRP, or DNAJC12(Table 2).
Out of the 20 PAH-deficient PKU patients, 19 were
homozygous and only 1 was compound heterozygote
(p.[Arg261Gln];[Leu197Phe]). Ten different variants
could be identified (c.1066-11G>A, c.1199+1G>C,
p.Glu57del, p.Lys363Asnfs*37, p.Leu197Phe, p.Arg261
Gln, p.Thr323del, p.Arg176*, p.Phe55Leufs*6, p.Tyr198
Serfs*136), among which p.Tyr198Serfs*136 and
p.Arg176* (each with 20%) were the most frequent,
followed by p.Phe55Leufs*6 with 15%. All variants had an
APV between 0 and 1.3, indicating classical PKU. The
exception was p.Leu197Phe (mPKU), where the APV
value was unknown. The pterins pattern (neopterin and
biopterin) in DBS was inconspicuous in all PKU patients
(Table 2).
Two patients diagnosed with the GTPCH deficiency
carried the same not previously described homozygous
GCH1 variant (p.His126Leu), and their DBS neopterin
and biopterin levels were very low (Table 2).
The patients with DHPR deficiency were all homozy-
gous for the following QDPR variants: p. Gly170Ser, c.436
+1G>C and c.545+1G>A. Interestingly, all these patients
had normal pterin patterns, with the exception of the ele-
vated DBS biopterin level in patients #26 and #27. Fur-
thermore, all patients in this subgroup were severely
affected by a developmental delay and one patient (#29)
passed away (Table 2).
The 3 PTPS-deficient patients were all children of first
degree cousin marriages, which might explain the homo-
zygous constellation of the PTS variants p.Thr67Met,
p.Asp94Gly (new), and p.Glu82Gly in these patients
(Table 2). The p.Glu82Gly variants was predicted by SIFT
algorithm to be tolerated (benign), but the patient (#31)
present with neurological problems similar to other
PTPS-deficient patients.
In all family members, the DBS pterins pattern and
DHPR activity were normal (data not shown).
The DNA of two patients with a normal pterins pat-
tern in DBS and with no mutation detected in the PAH,
GCH1, PTS, QDPR, GFRP and DNAJC12 genes under-
went whole exome sequencing, but again with no clear
diagnosis. In one patient who died (#33), a heterozygous
GCH1 variant of unknown significance (c.*721A>G) was
found in the 3'UTR region downstream of the stop
codon.
4 | DISCUSSION
Unfortunately, little information is available regarding
the prevalence of PKU in the Middle East in comparison
to other world regions, which might be explained by diffi-
culties in the implementation of national newborn
screening (NBS) programs.16 Only 10 Middle Eastern
countries, including Bahrain, Egypt, Iran, Israel, Kuwait,
Oman, Qatar, the State of Palestine, Saudi Arabia, and
the United Arab Emirates, have extensive national NBS
programs.17 However, the obtainable data suggest that
certain genetic disorders, such as PKU, occur more often
in Arabic than in Western countries, which can be
explained by several factors. First, the typical large Arabic
family structure becomes apparent if one compares the
crude birth rate of the Middle East and North Africa
(MENA) regions—23,1 per 1000 population (over 10,15
million births in 2017)—with the crude birth rate in the
United States of 11,8 per 1000 (3,8 million births in
2017).18
The incidence of PKU and other inherited metabolic
disorders in Jordan is not known, although the incidence
of inherited metabolic disorders is 1:1327 in Qatar, 1:1381
in Saudi Arabia, and 1:1555 in Oman, which could repre-
sent the type of population in Jordan, with high rates of
consanguinity.12 In 2006, the first PKU screening project
was started in certain areas of Jordan, and since 2010 the
Ministry of Health expanded it to a nationwide screening
program and provides care for the detected cases. By
2012, a total of 168 PKU patients were diagnosed, in
which only 32% were detected in the newborn period,
indicating that screening still needs to be improved. The
estimated incidence of PKU in Jordan is approximately
1:10 000 live births, and one of the main factors contrib-
uting to this high occurrence of PKU is the high degree
of consanguineous marriages.13
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Our study demonstrates a predominantly severe clas-
sic PKU phenotype in Jordanian patients, with two
exceptions (mPKU), all carrying homozygous mutations
with no residual PAH activity. Out of 10 PAH variants
detected, 2 were missense variants (p.Arg261Gln and p.
Leu197Phe with residual enzyme activity), 3 were frame
shifts, 2 were in-frame deletions, 2 were splice variants,
and one was a nonsense variant (Table 2). In all cases,
the metabolic phenotype fitted well with the observed
genotype and with the calculated genotypic phenotype
value (GPV; equal with the higher APV of the two
alleles), confirming the power of genotypic phenotype
prediction in PKU.8 All PKU patients adhered to a low-
Phe diet and their condition was under good control;
6 late-diagnosed patients were on anticonvulsants and
presented with psychomotor retardation, developmental
delay and seizures.
Disorders of BH4 metabolism account for only 1% to
2% of patients with HPA in Europeans,19 whereas they
are more common in some other ethnic groups. For
example, BH4 deficiency accounts for more than 10% of
all HPA patients in some countries in East Asia, includ-
ing Taiwan, Mainland China, Japan, South Korea, the
Philippines, Thailand and Malaysia,20 reaching up to
one-third of cases in some reports.21 The current study
also demonstrates a relatively frequent occurrence of BH4
deficiency in Jordan. A total of 11 (33%) out of 33 patients
with HPA were diagnosed with BH4 deficiency (6 DHPR,
3 PTPS, and 2 GTPCH). These findings align with previ-
ous reports from other countries in the region. A high
incidence of BH4 deficiency (12%) was reported for the
Kingdom of Saudi Arabia22 and Iran.23
Given the high prevalence of BH4 deficiency in Arab
countries and the fact that early diagnosis and treatment
can prevent brain damage, a systematic investigation of
BH4 deficiency is essential for all newborns and infants
with HPA. Simple tests for pterin and DHPR activity in
DBS enable the diagnosis of all forms of BH4 deficiency
presenting with HPA. With an expanded NBS program
and the wide availability of next-generation sequencing
methods, diagnostic testing will become available for the
region.
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